Literature DB >> 30206495

The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.

Tom Konert1,2, Jeroen B van de Kamer2, Jan-Jakob Sonke2, Wouter V Vogel1,2.   

Abstract

Advancements in functional imaging technology have allowed new possibilities in contouring of target volumes, monitoring therapy, and predicting treatment outcome in non-small cell lung cancer (NSCLC). Consequently, the role of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) has expanded in the last decades from a stand-alone diagnostic tool to a versatile instrument integrated with computed tomography (CT), with a prominent role in lung cancer radiotherapy. This review outlines the most recent literature on developments in FDG PET imaging for prognostication and radiotherapy target volume delineation (TVD) in NSCLC. We also describe the challenges facing the clinical implementation of these developments and present new ideas for future research.

Entities:  

Keywords:  Positron emission tomography (PET); non-small cell lung cancer (NSCLC); prognostication; radiomics; radiotherapy; review; target volume delineation (TVD)

Year:  2018        PMID： 30206495      PMCID： PMC6123188          DOI： 10.21037/jtd.2018.07.101

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  115 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

3.  Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.

Authors:  Gerben R Borst; José S A Belderbos; Ronald Boellaard; Emile F I Comans; Katrien De Jaeger; Adriaan A Lammertsma; Joos V Lebesque
Journal:  Eur J Cancer       Date:  2005-07       Impact factor: 9.162

4.  Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis.

Authors:  Roel J H M Steenbakkers; Joop C Duppen; Isabelle Fitton; Kirsten E I Deurloo; Lambert J Zijp; Emile F I Comans; Apollonia L J Uitterhoeve; Patrick T R Rodrigus; Gijsbert W P Kramer; Johan Bussink; Katrien De Jaeger; José S A Belderbos; Peter J C M Nowak; Marcel van Herk; Coen R N Rasch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-28       Impact factor: 7.038

5.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

6.  Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Authors:  Seung Hwan Moon; Su-Hee Cho; Lee Chun Park; Jun Ho Ji; Jong-Mu Sun; Jin Sock Ahn; Keunchil Park; Joon Young Choi; Myung-Ju Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-18       Impact factor: 9.236

7.  Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.

Authors:  Stephen S F Yip; John Kim; Thibaud P Coroller; Chintan Parmar; Emmanuel Rios Velazquez; Elizabeth Huynh; Raymond H Mak; Hugo J W L Aerts
Journal:  J Nucl Med       Date:  2016-09-29       Impact factor: 10.057

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 9.  Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

Authors:  I Bahce; M Yaqub; E F Smit; A A Lammertsma; G A M S van Dongen; N H Hendrikse
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

Review 10.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236
View more
  2 in total

Review 1.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057

2.  Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?

Authors:  Tom Konert; Sarah Everitt; Matthew D La Fontaine; Jeroen B van de Kamer; Michael P MacManus; Wouter V Vogel; Jason Callahan; Jan-Jakob Sonke
Journal:  PLoS One       Date:  2020-02-25       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.